JP2022550072A5 - - Google Patents

Info

Publication number
JP2022550072A5
JP2022550072A5 JP2022519181A JP2022519181A JP2022550072A5 JP 2022550072 A5 JP2022550072 A5 JP 2022550072A5 JP 2022519181 A JP2022519181 A JP 2022519181A JP 2022519181 A JP2022519181 A JP 2022519181A JP 2022550072 A5 JP2022550072 A5 JP 2022550072A5
Authority
JP
Japan
Prior art keywords
alkyl
pi4kiiiα
fam126
ttc7
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550072A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/118044 external-priority patent/WO2021057955A1/zh
Publication of JP2022550072A publication Critical patent/JP2022550072A/ja
Publication of JP2022550072A5 publication Critical patent/JP2022550072A5/ja
Pending legal-status Critical Current

Links

JP2022519181A 2019-09-27 2020-09-27 気分障害を処置するための方法 Pending JP2022550072A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019108548 2019-09-27
CNPCT/CN2019/108548 2019-09-27
CN202011009274.9 2020-09-23
CN202011009274 2020-09-23
PCT/CN2020/118044 WO2021057955A1 (zh) 2019-09-27 2020-09-27 一种治疗心境障碍的方法

Publications (2)

Publication Number Publication Date
JP2022550072A JP2022550072A (ja) 2022-11-30
JP2022550072A5 true JP2022550072A5 (cg-RX-API-DMAC10.html) 2023-10-10

Family

ID=75165596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519181A Pending JP2022550072A (ja) 2019-09-27 2020-09-27 気分障害を処置するための方法

Country Status (13)

Country Link
US (1) US20220362203A1 (cg-RX-API-DMAC10.html)
EP (1) EP4043013A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022550072A (cg-RX-API-DMAC10.html)
KR (1) KR20220122972A (cg-RX-API-DMAC10.html)
CN (2) CN114450003B (cg-RX-API-DMAC10.html)
AU (1) AU2020352345A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022005855A2 (cg-RX-API-DMAC10.html)
CA (1) CA3154723A1 (cg-RX-API-DMAC10.html)
IL (1) IL291639A (cg-RX-API-DMAC10.html)
MX (1) MX2022003720A (cg-RX-API-DMAC10.html)
PH (1) PH12022550572A1 (cg-RX-API-DMAC10.html)
TW (1) TW202126295A (cg-RX-API-DMAC10.html)
WO (1) WO2021057955A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
GB0020351D0 (en) * 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
KR20200011567A (ko) * 2015-04-30 2020-02-03 지앙수 누오-베타 파마수티칼 테크놀로지 컴퍼니, 리미티드 알츠하이머 질환을 치료하는데 사용되는 약물 및 치료 표적제를 스크리닝하는 방법
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
CN108721621B (zh) * 2017-04-14 2022-03-01 中国科学院上海高等研究院 抑制肝纤维化的小分子化合物及应用
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用

Similar Documents

Publication Publication Date Title
JP2021105002A5 (cg-RX-API-DMAC10.html)
US20190292135A1 (en) Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
Pitsch et al. Anti-epileptogenic and anti-convulsive effects of fingolimod in experimental temporal lobe epilepsy
US11912680B2 (en) Nitric oxide releasing prodrugs of MDA and MDMA
JP2015536132A5 (cg-RX-API-DMAC10.html)
JP2024518520A (ja) てんかんの処置用のカンナビジオール-c4誘導体
JP7199096B2 (ja) 皮膚疾患における治療標的としてのfabp4
JP2015520143A5 (cg-RX-API-DMAC10.html)
CN110840870A (zh) 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
JP2009536620A5 (cg-RX-API-DMAC10.html)
MX375082B (es) Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.
JP7184241B2 (ja) ベンズヒドリルチオアセトアミド化合物を有効成分として含む線維化疾患の治療用組成物
BR112020012629A2 (pt) estimulantes de sgc
JP2019519593A5 (cg-RX-API-DMAC10.html)
JP2018150239A (ja) β2GPI遺伝子発現抑制RNAi医薬組成物
Park et al. Double blockade of glioma cell proliferation and migration by temozolomide conjugated with NPPB, a chloride channel blocker
CN103200943A (zh) 2-甲酰胺环氨基尿素衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的药剂有获得性耐受性的疾病中的应用
JP2025507851A5 (cg-RX-API-DMAC10.html)
JP2021506958A (ja) Egfr阻害に関連する疾患を予防又は治療する方法
RU2005125919A (ru) Альфа-аминоамидные производные, применимые в качестве антимигренозных средств
JP2023518208A5 (cg-RX-API-DMAC10.html)
JP2014523426A5 (cg-RX-API-DMAC10.html)
CN115884789A (zh) Pi4k抑制剂的抗冠状病毒效果以及应用
JP2007536262A5 (cg-RX-API-DMAC10.html)